Design, synthesis and biological evaluation for docetaxel-loaded brain targeting liposome with “lock-in” function

References

• Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release 2001;74:63–7
   PubMed Web of Science ®Google Scholar
• Paulino AC, Teh BS. Treatment of brain tumors. N Engl J Med 2005;352:2350–3
   PubMedGoogle Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96
   PubMed Web of Science ®Google Scholar
• Gutman RL, Peacock G, Lu DR. Targeted drug delivery for brain cancer treatment. J Control Release 2000;65:31–41
   PubMed Web of Science ®Google Scholar
• Partap S, Fisher PG. Update on new treatments and developments in childhood brain tumors. Curr Opin Pediatr 2007;19:670--4
   PubMed Web of Science ®Google Scholar
• Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995;13:645–51
   PubMed Web of Science ®Google Scholar
• Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere (R)) in advanced ovarian cancer – an updated overview. Eur J Cancer 1997;33:2167–70
   PubMed Web of Science ®Google Scholar
• Walker RA, Jones JL, Chappell S, et al. Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Rev 1997;16:5–27
   PubMed Web of Science ®Google Scholar
• Pond GR, Berry WR, Galsky MD, et al. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2012;10:239–45
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99–114
   PubMed Web of Science ®Google Scholar
• Ardavanis A, Tryfonopoulos D, Yiotis I, et al. Nonallergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004;15:581–5
   PubMed Web of Science ®Google Scholar
• Cecchell R, Berezowski V, Lundquis S, et al. Modelling of the blood–brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6:650–61
   PubMed Web of Science ®Google Scholar
• Newton HB. Advances in strategies to improve drug delivery to brain tumors. Expert Rev Ther 2006;6:1495–509
   PubMedGoogle Scholar
• Barenholz Y. Liposome application:problems and prospects. Curr Opin Colloid Interface Sci 2001;6:66–77
   Web of Science ®Google Scholar
• Jain A, Chourasia MK, Soni V, et al. Brain-specific delivery of rifampin from lactyl stearate-coupled liposomes via monocarboxylic acid transporters. Am J Drug Deliv 2006;4:43--9
   Google Scholar
• Gao Y, Chen Y, Ji X, et al. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. ACS Nano 2011;5:9788–98
   PubMed Web of Science ®Google Scholar
• Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996;380:561–2
   PubMed Web of Science ®Google Scholar
• Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Control Release 1997;49:81--7
   Web of Science ®Google Scholar
• Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012;30:2256–72
   PubMed Web of Science ®Google Scholar
• Qutub AA, Hunt CA. Glucose transport to the brain: a systems model. Brain Res Brain Res Rev 2005;49:595–617
   PubMed Web of Science ®Google Scholar
• Regina A, Roux F, Revest PA. Glucose transport in immortalized rat brain capillary endothelial cells in vitro: transport activity and GLUT1 expression. Biochim Biophys Acta 1997;1335:135–43
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. Int Con Series 2005;1277:49–62
   Google Scholar
• Brightman MW. Morphology of blood-brain interfaces. Exp Eye Res 1977;25:1–25
   PubMed Web of Science ®Google Scholar
• Qin Y, Fan W, Chen HL, et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target 2010;18:536–49
   PubMed Web of Science ®Google Scholar
• Xie FL, Yiao N, Qin Y, et al. Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as linkers for brain targeting. Int J Nanomedicine 2012;7:163–75
   PubMed Web of Science ®Google Scholar
• Farrell CL, Pardridge WM. Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci U S A 1991;88:5779–83
   PubMed Web of Science ®Google Scholar
• Ishikura T, Senou T, Ishihara H, et al. Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds. Int J Pharm 1995;116:51–63
   Web of Science ®Google Scholar
• Fan W, Wu Y, Li XK, et al. Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen. Eur J Med Chem 2011;46:3651–61
   PubMed Web of Science ®Google Scholar
• Kumar VV, Chandrasekar D, Ramakrishna S, et al. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm 2007;335:167–75
   PubMed Web of Science ®Google Scholar
• Lee SW, Yun MH, Jeong SW, et al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. J Control Release 2011;155:262–71
   PubMed Web of Science ®Google Scholar
• Muthu MS, Feng SS. Pharmaceutical stability aspects of nanomedicines. Nanomedicine (London) 2009;4:857–60
   PubMed Web of Science ®Google Scholar
• Muthu MS, Kulkarnia SA, Xiong JQ, Feng SS. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm 2011;421:332–40
   PubMed Web of Science ®Google Scholar
• Kemper EM, Verheij M, Boogerd W, et al. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 2004;40:1269–74
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90–105
   PubMedGoogle Scholar
• Fan W, Yan CY, Qian S, et al. Design, synthesis and in vivo evaluation of sulfhydryl β-d-glucose cholesterols as ligands for brain targeting liposomes. Lett Drug Des Discov 2010;7:281–9
   Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97–109
   PubMed Web of Science ®Google Scholar
• Sheu MT, Chen SY, Chen LC, Ho HO. Influence of micelle solubilization by tocopheryl polyethylene glycol succinate (TPGS) on solubility enhancement and percutaneous penetration of estradiol. J Control Release 2003;88:55–368
   PubMedGoogle Scholar
• Nagamatsu S, Nakamichi Y, Inoue N, et al. Rat C6 glioma cell growth is related to glucose transport and metabolism. Biochem J 1996;319:477–82
   PubMed Web of Science ®Google Scholar